ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells
Abeona stands to collect mid-single-digit royalties on sales of Ultragenyx’s Fayuvi plus up to $30 million in commercial milestone payments as part of a licensing deal.
Stocktwits
More News
TWST Stock Hits Multi-Year High, But ‘Pharma Bro’ Martin Shkreli Calls Twist A Short
Twist traded as high as $163.70 on Thursday and finished the session about 9% higher near $156.
Stocktwits
FLNC Stock Tumbles After-Hours As Houston Plant Delays Force Another Guidance Cut
Fluence now expects fiscal 2026 revenue of about $2.4 billion, down from a prior midpoint of $3 billion.
Stocktwits
Why iShares Russell 2000 ETF Is Falling Wednesday
iShares Russell 2000 ETF is falling Wednesday, leading small-cap declines after a hawkish Fed rate decision and press conference.read more...
Benzinga
CIFR Stock Snaps 2-Day Slide After ERCOT Conditional Nod For 2 Major Data-Center Projects In Texas
Cipher Digital's Colchis site secured 1 GW of conditional baseload status, while Stingray received 100 MW.
Stocktwits
SRRK Shares Pull Back After FDA Approval For Genetic Disease Drug — But Wall Street Hikes Price Targets
On a call on Monday, the company set a list price of $11,659 per vial of Isembyld, or about $310,000 a year for a typical patient.
Stocktwits
DFTX Stock Climbs As High As 12% On ‘Unprecedented’ Anxiety Data For LSD-Based Drug
The company said that the Panorama trial of DT120, a fast-dissolving tablet form of the psychedelic drug lysergide, or LSD, met its main goal in adults with generalized anxiety disorder.
Stocktwits
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
FDA approved Isembyld for patients age two and older who already take certain spinal muscular atrophy drugs.
Stocktwits
Wall Street Sounds Positive On BRZE Stock Despite Post-Earnings Decline – These Analysts See Buying Opportunity
Raymond James, UBS, and Canaccord raised their price targets on the stock, while Stifel and Stephens called the post-earnings weakness a buying opportunity.
Stocktwits
PHAT Stock Falls 7% As Leerink Sees Little Near-Term Upside — CEO Plays Down Upcoming Rival
Leerink said that VOQUEZNA competes in a “highly genericized” gastroesophageal reflux disease market against long-available proton pump inhibitors (PPI).
